Browsing Barts Cancer Institute by Subject "4.1 Discovery and preclinical testing of markers and technologies"
Now showing items 1-2 of 2
-
Abstract P6-10-05: Mutations in the RNA Splicing Factor SF3B1 drive endocrine therapy resistance and confer a targetable replication stress response defect through PARP inhibition
(American Association for Cancer Research (AACR), 2023-03-01)